TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Study of the Treatment of Urodynamic Stress Incontinence: the Tension Free Vaginal Tape (TVT) Versus the Miniarc Sling.
Brief Summary: The aim of this study is to assess whether the Miniarc suburethral sling is equivalent to the TVT in the treatment of women with urodynamic stress incontinence (USI). If equivalence is proven, the advantages to women with USI will be potentially significant since the Miniarc may be carried out as an office based procedure, negating the need for an anaesthetic and hospital admission. The investigators null hypothesis is that there is no difference in subjective or objective outcome between the TVT and the Miniarc in the treatment of USI.

Eligible women will be initially assessed with a full history and examination, King's Health Questionnaire and twin channel subtraction cystometry. They will be randomised (using a series of numbered opaque envelopes) to undergo either the TVT or Miniarc. Follow up will be at 6 weeks, with a subjective outcome measure and at 6 months with a repeat subjective assessment and repeat twin channel cystometry.


Options:
A: Arm Label: Ajust sling; Type: EXPERIMENTAL; Interventions: Procedure: Ajust system, Procedure: TVT/TVT-O | Arm Label: TVT/TVT-O, polypropylne slings; Type: EXPERIMENTAL; Interventions: Procedure: Ajust system, Procedure: TVT/TVT-O | Intervention Type: PROCEDURE; Name: Ajust system; Assigned to Arm(s): Ajust sling, TVT/TVT-O, polypropylne slings | Intervention Type: PROCEDURE; Name: TVT/TVT-O; Assigned to Arm(s): Ajust sling, TVT/TVT-O, polypropylne slings
B: Arm Label: Single-incision Mini-slings (SIMS- Ajust); Type: EXPERIMENTAL; Interventions: Procedure: sub-urethral tape (TVT-O) | Arm Label: standared med urethral sling (SMUS); Type: OTHER; Interventions: Other: stand standard mid-urethral sling (TVT-O) | Intervention Type: PROCEDURE; Name: sub-urethral tape (TVT-O); Assigned to Arm(s): Single-incision Mini-slings (SIMS- Ajust) | Intervention Type: OTHER; Name: stand standard mid-urethral sling (TVT-O); Assigned to Arm(s): standared med urethral sling (SMUS)
C: Arm Label: TVT; Type: ACTIVE_COMPARATOR; Interventions: Device: Tension Free Vaginal Tape | Arm Label: Miniarc; Type: EXPERIMENTAL; Interventions: Device: Miniarc | Intervention Type: DEVICE; Name: Tension Free Vaginal Tape; Assigned to Arm(s): TVT | Intervention Type: DEVICE; Name: Miniarc; Assigned to Arm(s): Miniarc
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Device: tension-free vaginal tape | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Device: TVT-SECUR device | Intervention Type: DEVICE; Name: tension-free vaginal tape; Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: TVT-SECUR device; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Medication Adherence Enhancement in Heart Transplant Recipients: a Randomized Clinical Trial
Brief Summary: Medication-related non-adherence increases the risk of rejections and associated graft loss after solid organ transplantation. A randomized controlled intervention will use adherence enhancing strategies out of a larger sample of 300 heart transplant recipients. Non-Adherence will be assessed by patients' self-report and based on immunosuppression level. All non-adherent patients will be randomly designed to either intervention or control group. Multi-module interventions include patient education, electronic medication event monitoring, and a combined behavior and symptom management. Longitudinal follow-up is envisioned after initial intervention.


Options:
A: Arm Label: Video education + adherence contract; Type: EXPERIMENTAL; Interventions: Behavioral: Video education + adherence contract | Arm Label: Standard education; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Video education + adherence contract; Assigned to Arm(s): Video education + adherence contract
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: behavioral adaptation and symptom management | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: behavioral adaptation and symptom management; Assigned to Arm(s): 1
C: Arm Label: Prograf®; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tacrolimus - Prograf® twice daily formulation | Arm Label: Advagraf®; Type: EXPERIMENTAL; Interventions: Drug: Tacrolimus - Advagraf® once daily formulation | Intervention Type: DRUG; Name: Tacrolimus - Prograf® twice daily formulation; Assigned to Arm(s): Prograf® | Intervention Type: DRUG; Name: Tacrolimus - Advagraf® once daily formulation; Assigned to Arm(s): Advagraf®
D: Arm Label: Standard of Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: mHealth Intervention; Type: EXPERIMENTAL; Interventions: Other: mHealth Intervention | Intervention Type: OTHER; Name: mHealth Intervention; Assigned to Arm(s): mHealth Intervention

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Safety and Efficacy of Simplified Antibiotic Regimens for Outpatient Treatment of Suspected Sepsis in Neonates and Young Infants in Bangladesh
Brief Summary: The primary aim is to establish the non-inferiority of several simplified, home-based antibiotic regimens compared to the standard course of parenteral antibiotics for the empiric treatment of suspected sepsis in Bangladeshi young infants whose parents refuse hospitalization. Three alternative regimens will be compared with a standard (reference) regimen of injectable procaine-benzyl penicillin and gentamicin once daily each for seven days. Alternative regimens are (1) injectable gentamicin once daily and oral amoxicillin twice daily for seven days; (2) injectable penicillin and gentamicin once daily for two days followed by oral amoxicillin twice daily for five days; and (3) injectable gentamicin once daily and oral amoxicillin twice daily for two days followed by oral amoxicillin twice daily for five days.

Hypothesis

The proportion who fails treatment will be 10 percent in the reference group and the alternative treatment groups. An alternative therapy will be considered non-inferior to the standard therapy if the failure rate in the alternative therapy exceeds the failure rate in the injectable therapy by less than 5 absolute percentage points.

Secondary Objectives:

* To identify baseline clinical predictors of treatment failure in severe infections in young infants.
* To determine the proportion of relapse (young infants who were considered cured by day 7 but developed any of the signs of suspected severe infection by day 14).


Options:
A: Arm Label: Breastfeeding promotion intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Breastfeeding promotion intervention | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Breastfeeding promotion intervention; Assigned to Arm(s): Breastfeeding promotion intervention
B: Intervention Type: BEHAVIORAL; Name: Newborn Thermal Care Practice; Assigned to Arm(s): N/A
C: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Community Health Workers; Type: EXPERIMENTAL; Interventions: Behavioral: community health workers | Intervention Type: BEHAVIORAL; Name: community health workers; Assigned to Arm(s): Community Health Workers
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gentamicin & Amoxicillin x 7days | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Penicillin & gentamicin x 2 d + Amoxicillin X 5 d | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard reference therapy | Intervention Type: DRUG; Name: Gentamicin & Amoxicillin x 7days; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Penicillin & gentamicin x 2 d + Amoxicillin X 5 d; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Standard reference therapy; Assigned to Arm(s): 3

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Safety and Efficacy of Simplified Antibiotic Regimens for Outpatient Treatment of Suspected Sepsis in Neonates and Young Infants in Bangladesh
Brief Summary: The primary aim is to establish the non-inferiority of several simplified, home-based antibiotic regimens compared to the standard course of parenteral antibiotics for the empiric treatment of suspected sepsis in Bangladeshi young infants whose parents refuse hospitalization. Three alternative regimens will be compared with a standard (reference) regimen of injectable procaine-benzyl penicillin and gentamicin once daily each for seven days. Alternative regimens are (1) injectable gentamicin once daily and oral amoxicillin twice daily for seven days; (2) injectable penicillin and gentamicin once daily for two days followed by oral amoxicillin twice daily for five days; and (3) injectable gentamicin once daily and oral amoxicillin twice daily for two days followed by oral amoxicillin twice daily for five days.

Hypothesis

The proportion who fails treatment will be 10 percent in the reference group and the alternative treatment groups. An alternative therapy will be considered non-inferior to the standard therapy if the failure rate in the alternative therapy exceeds the failure rate in the injectable therapy by less than 5 absolute percentage points.

Secondary Objectives:

* To identify baseline clinical predictors of treatment failure in severe infections in young infants.
* To determine the proportion of relapse (young infants who were considered cured by day 7 but developed any of the signs of suspected severe infection by day 14).


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gentamicin & Amoxicillin x 7days | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Penicillin & gentamicin x 2 d + Amoxicillin X 5 d | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard reference therapy | Intervention Type: DRUG; Name: Gentamicin & Amoxicillin x 7days; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Penicillin & gentamicin x 2 d + Amoxicillin X 5 d; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Standard reference therapy; Assigned to Arm(s): 3
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Coartem and amoxicillin | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Coartem | Intervention Type: DRUG; Name: Coartem and amoxicillin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Coartem; Assigned to Arm(s): 2
C: Intervention Type: BEHAVIORAL; Name: Improved management of severe neonatal infections; Assigned to Arm(s): N/A
D: Arm Label: Arm1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Community Based | Intervention Type: OTHER; Name: Community Based; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-Label, Multi-Center Controlled Clinical Trial Of Eculizumab in Adolescent Patients With Plasma Therapy-Sensitive Atypical Hemolytic Uremic Syndrome (AHUS)
Brief Summary: The purpose of this study is to determine whether eculizumab is safe and effective in the treatment of adolescent patients with plasma therapy-sensitive Atypical Hemolytic-Uremic Syndrome (aHUS).


Options:
A: N/A
B: Arm Label: eculizumab; Type: EXPERIMENTAL; Interventions: Drug: eculizumab | Intervention Type: DRUG; Name: eculizumab; Assigned to Arm(s): eculizumab
C: Arm Label: OMS721; Type: EXPERIMENTAL; Interventions: Biological: OMS721 | Intervention Type: BIOLOGICAL; Name: OMS721; Assigned to Arm(s): OMS721
D: Arm Label: Eculizumab; Type: EXPERIMENTAL; Interventions: Drug: eculizumab | Intervention Type: DRUG; Name: eculizumab; Assigned to Arm(s): Eculizumab

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-Label, Multi-Center Controlled Clinical Trial Of Eculizumab in Adolescent Patients With Plasma Therapy-Sensitive Atypical Hemolytic Uremic Syndrome (AHUS)
Brief Summary: The purpose of this study is to determine whether eculizumab is safe and effective in the treatment of adolescent patients with plasma therapy-sensitive Atypical Hemolytic-Uremic Syndrome (aHUS).


Options:
A: Arm Label: Group 1; Type: EXPERIMENTAL; Interventions: Drug: Immune Globulin IV (Human), 10% Caprylate/Chromatography Purified | Arm Label: Group 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Albumin (Human) 25%, United States Pharmacopeia (USP) | Intervention Type: DRUG; Name: Immune Globulin IV (Human), 10% Caprylate/Chromatography Purified; Assigned to Arm(s): Group 1 | Intervention Type: DRUG; Name: Albumin (Human) 25%, United States Pharmacopeia (USP); Assigned to Arm(s): Group 2
B: Arm Label: GBS; Type: N/A; Interventions: N/A | Arm Label: NC; Type: N/A; Interventions: N/A | Arm Label: IC; Type: N/A; Interventions: N/A | Arm Label: OND; Type: N/A; Interventions: N/A
C: Arm Label: Eculizumab; Type: EXPERIMENTAL; Interventions: Drug: eculizumab | Intervention Type: DRUG; Name: eculizumab; Assigned to Arm(s): Eculizumab
D: Arm Label: Eculizumab; Type: EXPERIMENTAL; Interventions: Drug: Eculizumab | Intervention Type: DRUG; Name: Eculizumab; Assigned to Arm(s): Eculizumab

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-Label, Multi-Center Controlled Clinical Trial of Eculizumab in Adult Patients With Plasma Therapy-Resistant Atypical Hemolytic Uremic Syndrome (aHUS)
Brief Summary: The purpose of this study is to determine whether eculizumab is safe and effective in the treatment of adult patients with plasma therapy-resistant Atypical Hemolytic-Uremic Syndrome (aHUS).


Options:
A: Arm Label: Eculizumab; Type: EXPERIMENTAL; Interventions: Drug: Eculizumab | Intervention Type: DRUG; Name: Eculizumab; Assigned to Arm(s): Eculizumab
B: Arm Label: Eculizumab; Type: EXPERIMENTAL; Interventions: Drug: eculizumab | Intervention Type: DRUG; Name: eculizumab; Assigned to Arm(s): Eculizumab
C: Arm Label: Eculizumab; Type: EXPERIMENTAL; Interventions: Drug: Eculizumab | Intervention Type: DRUG; Name: Eculizumab; Assigned to Arm(s): Eculizumab
D: Arm Label: OMS721 low dose; Type: EXPERIMENTAL; Interventions: Biological: OMS721 | Arm Label: OMS721 medium dose; Type: EXPERIMENTAL; Interventions: Biological: OMS721 | Arm Label: OMS721 high dose; Type: EXPERIMENTAL; Interventions: Biological: OMS721 | Intervention Type: BIOLOGICAL; Name: OMS721; Assigned to Arm(s): OMS721 high dose, OMS721 low dose, OMS721 medium dose

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-Label, Multi-Center Controlled Clinical Trial of Eculizumab in Adult Patients With Plasma Therapy-Resistant Atypical Hemolytic Uremic Syndrome (aHUS)
Brief Summary: The purpose of this study is to determine whether eculizumab is safe and effective in the treatment of adult patients with plasma therapy-resistant Atypical Hemolytic-Uremic Syndrome (aHUS).


Options:
A: Arm Label: Eculizumab; Type: EXPERIMENTAL; Interventions: Drug: Eculizumab | Intervention Type: DRUG; Name: Eculizumab; Assigned to Arm(s): Eculizumab
B: Arm Label: GBS; Type: N/A; Interventions: N/A | Arm Label: NC; Type: N/A; Interventions: N/A | Arm Label: IC; Type: N/A; Interventions: N/A | Arm Label: OND; Type: N/A; Interventions: N/A
C: Arm Label: Eculizumab; Type: EXPERIMENTAL; Interventions: Drug: Eculizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: N/A | Intervention Type: DRUG; Name: Eculizumab; Assigned to Arm(s): Eculizumab
D: Arm Label: Group 1; Type: EXPERIMENTAL; Interventions: Drug: Immune Globulin IV (Human), 10% Caprylate/Chromatography Purified | Arm Label: Group 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Albumin (Human) 25%, United States Pharmacopeia (USP) | Intervention Type: DRUG; Name: Immune Globulin IV (Human), 10% Caprylate/Chromatography Purified; Assigned to Arm(s): Group 1 | Intervention Type: DRUG; Name: Albumin (Human) 25%, United States Pharmacopeia (USP); Assigned to Arm(s): Group 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effectiveness of an E-learning Program About Child Maltreatment for Nurses on an A&E Department: a Randomised Controlled Trial
Brief Summary: The purpose of this study is to determine whether the e-learning program about the recognition of child maltreatment is effective in nurses on the A\&E department compared to a control group.


Options:
A: Arm Label: interactive lecture module; Type: ACTIVE_COMPARATOR; Interventions: Other: interactive lecture | Arm Label: online educational module; Type: ACTIVE_COMPARATOR; Interventions: Other: online education | Intervention Type: OTHER; Name: interactive lecture; Assigned to Arm(s): interactive lecture module | Intervention Type: OTHER; Name: online education; Assigned to Arm(s): online educational module
B: Arm Label: iLook Out for Child Abuse; Type: EXPERIMENTAL; Interventions: Other: iLook Out for Child Abuse | Intervention Type: OTHER; Name: iLook Out for Child Abuse; Assigned to Arm(s): iLook Out for Child Abuse
C: Arm Label: iLookOut; Type: EXPERIMENTAL; Interventions: Other: iLook Out for Child Abuse | Arm Label: Standard; Type: ACTIVE_COMPARATOR; Interventions: Other: iLook Out for Child Abuse | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: iLook Out for Child Abuse; Assigned to Arm(s): Standard, iLookOut
D: Arm Label: E-learning program; Type: N/A; Interventions: Other: E-learning program | Arm Label: control group; Type: N/A; Interventions: N/A | Intervention Type: OTHER; Name: E-learning program; Assigned to Arm(s): E-learning program

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effectiveness of an E-learning Program About Child Maltreatment for Nurses on an A&E Department: a Randomised Controlled Trial
Brief Summary: The purpose of this study is to determine whether the e-learning program about the recognition of child maltreatment is effective in nurses on the A\&E department compared to a control group.


Options:
A: Arm Label: E-learning program; Type: N/A; Interventions: Other: E-learning program | Arm Label: control group; Type: N/A; Interventions: N/A | Intervention Type: OTHER; Name: E-learning program; Assigned to Arm(s): E-learning program
B: Arm Label: OSS Phase 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Training and supervision, Behavioral: Integrated Management of Infectious Disease (IMID) | Arm Label: OSS Phase 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Training and Supervision, Behavioral: Integrated Management of Infectious Disease (IMID) | Intervention Type: BEHAVIORAL; Name: Training and supervision; Assigned to Arm(s): OSS Phase 1 | Intervention Type: BEHAVIORAL; Name: Training and Supervision; Assigned to Arm(s): OSS Phase 2 | Intervention Type: BEHAVIORAL; Name: Integrated Management of Infectious Disease (IMID); Assigned to Arm(s): OSS Phase 1 | Intervention Type: BEHAVIORAL; Name: Integrated Management of Infectious Disease (IMID); Assigned to Arm(s): OSS Phase 2
C: Intervention Type: BEHAVIORAL; Name: knowledge-adaptive Web-based instruction; Assigned to Arm(s): N/A
D: Arm Label: Intervention; Type: OTHER; Interventions: Other: E-learning | Arm Label: Control; Type: OTHER; Interventions: Other: E-learning | Intervention Type: OTHER; Name: E-learning; Assigned to Arm(s): Control, Intervention

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-Label, Multi-Center Controlled Clinical Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Resistant Atypical Hemolytic Uremic Syndrome (aHUS)
Brief Summary: The purpose of this study is to determine whether eculizumab is safe and effective in the treatment of adolescent patients with plasma therapy-resistant Atypical Hemolytic-Uremic Syndrome (aHUS).


Options:
A: Arm Label: Eculizumab; Type: EXPERIMENTAL; Interventions: Drug: Eculizumab | Intervention Type: DRUG; Name: Eculizumab; Assigned to Arm(s): Eculizumab
B: Arm Label: Ravulizumab; Type: EXPERIMENTAL; Interventions: Biological: Ravulizumab | Arm Label: Eculizumab; Type: ACTIVE_COMPARATOR; Interventions: Biological: Ravulizumab, Biological: Eculizumab | Intervention Type: BIOLOGICAL; Name: Ravulizumab; Assigned to Arm(s): Eculizumab, Ravulizumab | Intervention Type: BIOLOGICAL; Name: Eculizumab; Assigned to Arm(s): Eculizumab
C: Arm Label: Eculizumab; Type: EXPERIMENTAL; Interventions: Drug: Eculizumab | Intervention Type: DRUG; Name: Eculizumab; Assigned to Arm(s): Eculizumab
D: Arm Label: Eculizumab; Type: EXPERIMENTAL; Interventions: Drug: eculizumab | Intervention Type: DRUG; Name: eculizumab; Assigned to Arm(s): Eculizumab

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-Label, Multi-Center Controlled Clinical Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Resistant Atypical Hemolytic Uremic Syndrome (aHUS)
Brief Summary: The purpose of this study is to determine whether eculizumab is safe and effective in the treatment of adolescent patients with plasma therapy-resistant Atypical Hemolytic-Uremic Syndrome (aHUS).


Options:
A: Arm Label: Eculizumab; Type: EXPERIMENTAL; Interventions: Drug: eculizumab | Intervention Type: DRUG; Name: eculizumab; Assigned to Arm(s): Eculizumab
B: Arm Label: Eculizumab; Type: EXPERIMENTAL; Interventions: Drug: Eculizumab | Intervention Type: DRUG; Name: Eculizumab; Assigned to Arm(s): Eculizumab
C: Arm Label: eculizumab; Type: EXPERIMENTAL; Interventions: Drug: eculizumab | Intervention Type: DRUG; Name: eculizumab; Assigned to Arm(s): eculizumab
D: Arm Label: Eculizumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Eculizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Eculizumab; Assigned to Arm(s): Eculizumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Study to Assess the Efficacy and Safety of Olanzapine and Fluoxetine Combination Versus Placebo in Patients Ages 10-17 in the Treatment of Major Depressive Episodes Associated With Bipolar I Disorder
Brief Summary: The main goal of this study is to help answer the following research question(s) and not to treat the child's illness.

* Can this study drug make children with bipolar depression feel better?
* Does this study drug work better than a placebo (sugar pill)?
* Does this study drug cause side effects in children who take it?
* Is this drug safe to use in children? (The study drug is a mixture of olanzapine and fluoxetine)


Options:
A: Intervention Type: DRUG; Name: DVS-SR 50 mg; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: DVS-SR 100 mg; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): N/A
B: Arm Label: Olanzapine/Fluoxetine Combination; Type: EXPERIMENTAL; Interventions: Drug: Olanzapine Fluoxetine Combination (OFC) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Olanzapine Fluoxetine Combination (OFC); Assigned to Arm(s): Olanzapine/Fluoxetine Combination | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: Fluoxetine; Assigned to Arm(s): N/A
D: Arm Label: Desvenlafaxine Succinate Sustained-Release; Type: EXPERIMENTAL; Interventions: Drug: DVS SR | Intervention Type: DRUG; Name: DVS SR; Assigned to Arm(s): Desvenlafaxine Succinate Sustained-Release

Answer: B